Compared to its American brethren, Altria Group, which had an 8.6% cigarette volume decline last quarter, Philip Morris ...

Zyn has taken the U.S. by storm. The nicotine pouch brand's boom came at an opportune time for parent company Philip Morris ...

Shares of Philip Morris extended their recent bounce Thursday after the U.S. Food and Drug Administration authorized the ...

Philip Morris International Inc. (PMI) (NYSE: PM) will host a live audio webcast at on Thursday, February 6, 2025, at 9:00 a ...

The U.S. Food and Drug Administration (FDA), the US governmental authority responsible for regulating foods and medical ...

Barclays analyst Gaurav Jain maintained a Buy rating on Philip Morris (PM – Research Report) today and set a price target of $145.00. The ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

In a report released yesterday, Eric Serotta from Morgan Stanley initiated coverage with a Buy rating on Philip Morris (PM – Research Report) ...

Philip Morris outperformed the S&P 500 in 2024 ... Despite regulatory risks, PM's diversified portfolio, including smoke-free products like IQOS and ZYN, positions it for continued revenue ...

IQOS's success in Egypt signals a promising opportunity for the introduction of additional smoke-free products to the market, ...

Zyn's growth comes as Philip Morris looks to transition more to smokeless products. "Their goal is by 2030, two-thirds of their revenue should be smoke-free. And ultimately they'd love it to be 100%.